0001654954-19-005335.txt : 20190506 0001654954-19-005335.hdr.sgml : 20190506 20190506161642 ACCESSION NUMBER: 0001654954-19-005335 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20190502 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20190506 DATE AS OF CHANGE: 20190506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Medite Cancer Diagnostics, Inc. CENTRAL INDEX KEY: 0000075439 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 364296006 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-00935 FILM NUMBER: 19799518 BUSINESS ADDRESS: STREET 1: 414 NORTH ORLEANS STREET STREET 2: SUITE 502 CITY: CHICAGO STATE: IL ZIP: 60610 BUSINESS PHONE: 4078490290 MAIL ADDRESS: STREET 1: 414 NORTH ORLEANS STREET STREET 2: SUITE 502 CITY: CHICAGO STATE: IL ZIP: 60610 FORMER COMPANY: FORMER CONFORMED NAME: CytoCore Inc DATE OF NAME CHANGE: 20060815 FORMER COMPANY: FORMER CONFORMED NAME: MOLECULAR DIAGNOSTICS INC DATE OF NAME CHANGE: 20011009 FORMER COMPANY: FORMER CONFORMED NAME: AMPERSAND MEDICAL CORP DATE OF NAME CHANGE: 19990527 8-K 1 mdit8k050219.htm CURRENT REPORT 8K MDIT
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
  
Date of report (Date of earliest event reported)  May 2, 2019
 
MEDITE CANCER DIAGNOSTICS, INC.
(Exact Name of Registrant as Specified in Charter)
 
Delaware
(State or Other Jurisdiction of Incorporation)
 
333-143570
36-4296006
(Commission File Number)
(IRS Employer Identification No.)
 
10524 Moss Park Rd., Ste. 204-357
 
Orlando, FL
32832
(Address of Principal Executive Offices)
(Zip Code)
 
(407) 996-9630
(Registrant’s telephone number, including area code)
 
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 
 Item 5.02
 Departure of Directors or Principal Officers, Election of Directors, Appointment of Principal Officers.
 
On May 2, 2019, the Board of Directors (the “Board”) of MEDITE Cancer Diagnostics, Inc. (the “Company”) accepted the resignation of its Chief Executive Officer, President and Director, Elmar A. Dave, effective immediately.
 
 
 
 
 Item 9.01
 Financial Statements and Exhibits
 
Exhibit No.
 
 Description
 
 Resignation Letter of Elmar A. Dave dated May 2, 2019


 
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
MEDITE CANCER DIAGNOSTICS, INC.
 
 
 
 
 
 
Date: May 6, 2019
By:
/s/ William Austin Lewis IV
 
 
William Austin Lewis IV
 
 
Chairman of the Board
2

 
 
 EX-99.1 2 ex99-1.htm ADDITIONAL EXHIBITS Blueprint
 
Exhibit 99.1 
 
 

 
May 2nd, 2019
 
 
MEDITE CANCER DIAGNOSTICS, INC.
W. Austin Lewis IV, Chairman of the Board
10524 Moss Park Road, Ste 204-357
Orlando, Florida, 32805
 
 
RESIGNATION FROM MY POSITION AS CEO AND BOARD MEMBER AT MEDITE CANCER DIAGNOSTICS
 
 
Dear Austin Lewis:
 
I hereby respectfully resign from my position as Chief Executive Officer and Member of the Board of Directors of Medite Cancer Diagnostics, Inc. effective the date of this letter.
 
I appreciate the support during my time at Medite and truly enjoyed serving the company in this capacity during the recent restructuring period in Germany and the United States.
 
 
Most sincerely,
 
Elmar A. Dave
 
/s/ Elmar A. Dave
 
 
 
 
 
This resignation letter was received by:
 
________________________________ Date:_______________
 
W. Austin Lewis
Chairman of the Board
Medite Cancer Diagnostics, Inc.